HK1056182A1 - Reshaped monoclonal antibodies against an immunoglobulin isotype - Google Patents

Reshaped monoclonal antibodies against an immunoglobulin isotype

Info

Publication number: HK1056182A1
Authority: HK; Hong Kong
Prior art keywords: monoclonal antibodies; antibodies against; immunoglobulin isotype; reshaped; reshaped monoclonal
Prior art date: 1992-09-24

Application number

HK03108492A

Other languages

English (en)

Inventor

Norman Hardman

Frand Kolbinger

Jose Saldanha

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-24

Filing date

2003-11-21

Publication date

2004-02-06

1992-09-24 Priority claimed from GB929220228A external-priority patent/GB9220228D0/en

2003-11-21 Application filed by Novartis Ag filed Critical Novartis Ag

2004-02-06 Publication of HK1056182A1 publication Critical patent/HK1056182A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Dermatology (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

HK03108492A 1992-09-24 2003-11-21 Reshaped monoclonal antibodies against an immunoglobulin isotype HK1056182A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929220228A GB9220228D0 (en)	1992-09-24	1992-09-24	Reshaped monoclonal antibodies against an immunologlobulin isotype
US95280292A	1992-09-25	1992-09-25

Publications (1)

Publication Number	Publication Date
HK1056182A1 true HK1056182A1 (en)	2004-02-06

Family

ID=26301683

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK03108492A HK1056182A1 (en)	1992-09-24	2003-11-21	Reshaped monoclonal antibodies against an immunoglobulin isotype

Country Status (18)

Country	Link
EP (2)	EP1452542A3 (zh)
JP (2)	JP3636737B2 (zh)
KR (1)	KR100298608B1 (zh)
CN (2)	CN1078250C (zh)
AT (1)	ATE264388T1 (zh)
AU (1)	AU675449B2 (zh)
CA (1)	CA2106719C (zh)
CY (1)	CY2583B2 (zh)
DE (1)	DE69333484T2 (zh)
DK (1)	DK0589840T3 (zh)
ES (1)	ES2219640T3 (zh)
FI (2)	FI114550B (zh)
HK (1)	HK1056182A1 (zh)
IL (2)	IL107049A (zh)
MX (1)	MX9305920A (zh)
NO (1)	NO318210B1 (zh)
NZ (1)	NZ248743A (zh)
PT (1)	PT589840E (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
ZA966075B (en) *	1995-07-27	1998-01-19	Genentech Inc	Protein formulation.
US6685940B2 (en)	1995-07-27	2004-02-03	Genentech, Inc.	Protein formulation
AU7156996A (en) *	1995-09-13	1997-04-01	Genentech Inc.	Methods for treatment of interstitial cystitis
US6127524A (en) *	1996-10-18	2000-10-03	Dade Behring Inc.	Binding molecules and computer-based methods of increasing the binding affinity thereof
AU2103699A (en) *	1998-01-29	1999-08-16	Tse Wen Chang	Treating atopic dermatitis with ige antagonists
US9320792B2 (en)	2002-11-08	2016-04-26	Ablynx N.V.	Pulmonary administration of immunoglobulin single variable domains and constructs thereof
EP1900753B1 (en)	2002-11-08	2017-08-09	Ablynx N.V.	Method of administering therapeutic polypeptides, and polypeptides therefor
AU2003283137B8 (en) *	2002-11-08	2010-07-29	Ablynx N.V.	Camelidae antibodies against immunoglobulin E and use thereof for the treatment of allergic disorders
US20060034845A1 (en)	2002-11-08	2006-02-16	Karen Silence	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
AU2004209638B2 (en) *	2003-02-01	2011-02-03	Tanox, Inc.	High affinity anti-human IgE antibodies
AU2004315197B2 (en) *	2004-02-02	2009-06-04	Tanox, Inc.	Identification of novel IgE epitopes
JP5823867B2 (ja)	2008-10-29	2015-11-25	アブリンクスエン．ヴェー．	単一ドメイン抗原結合分子の製剤
KR20110079693A (ko)	2008-10-29	2011-07-07	와이어쓰 엘엘씨	단일 도메인 항원 결합 분자의 정제 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3853636T3 (de) *	1987-12-31	1999-04-08	Tanox Biosystems, Inc., Houston, Tex.	Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
US5104604A (en) *	1989-10-05	1992-04-14	Dexter Electronic Materials Div. Of Dexter Corp.	Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound
JP2988635B2 (ja) *	1990-09-18	1999-12-13	塩野義製薬株式会社	ヒトＩｇＥに対するモノクローナル抗体
WO1992017207A1 (en) *	1991-03-26	1992-10-15	Tanox Biosystems, Inc.	MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS
AU2498192A (en) *	1991-08-14	1993-03-16	Genentech Inc.	Immunoglobulin variants for specific fc epsilon receptors

1993
- 1993-09-15 DE DE69333484T patent/DE69333484T2/de not_active Expired - Lifetime
- 1993-09-15 AT AT93810653T patent/ATE264388T1/de not_active IP Right Cessation
- 1993-09-15 ES ES93810653T patent/ES2219640T3/es not_active Expired - Lifetime
- 1993-09-15 PT PT93810653T patent/PT589840E/pt unknown
- 1993-09-15 EP EP04008222A patent/EP1452542A3/en not_active Withdrawn
- 1993-09-15 DK DK93810653T patent/DK0589840T3/da active
- 1993-09-15 EP EP93810653A patent/EP0589840B1/en not_active Expired - Lifetime
- 1993-09-20 AU AU47488/93A patent/AU675449B2/en not_active Ceased
- 1993-09-20 IL IL107049A patent/IL107049A/en not_active IP Right Cessation
- 1993-09-20 IL IL173988A patent/IL173988A0/en unknown
- 1993-09-22 FI FI934145A patent/FI114550B/fi active IP Right Grant
- 1993-09-22 CA CA002106719A patent/CA2106719C/en not_active Expired - Fee Related
- 1993-09-22 NZ NZ248743A patent/NZ248743A/en not_active IP Right Cessation
- 1993-09-23 NO NO19933394A patent/NO318210B1/no not_active IP Right Cessation
- 1993-09-24 KR KR1019930019631A patent/KR100298608B1/ko not_active IP Right Cessation
- 1993-09-24 MX MX9305920A patent/MX9305920A/es not_active IP Right Cessation
- 1993-09-24 JP JP23818093A patent/JP3636737B2/ja not_active Expired - Fee Related
- 1993-09-24 CN CN93119845A patent/CN1078250C/zh not_active Expired - Fee Related
2001
- 2001-12-14 CN CNB011436433A patent/CN1254487C/zh not_active Expired - Fee Related
2003
- 2003-11-21 HK HK03108492A patent/HK1056182A1/xx not_active IP Right Cessation
2004
- 2004-05-19 FI FI20040696A patent/FI115838B/fi active IP Right Grant
- 2004-07-07 JP JP2004201096A patent/JP3718214B2/ja not_active Expired - Fee Related
2005
- 2005-09-08 CY CY0500048A patent/CY2583B2/xx unknown

Also Published As

Publication number	Publication date
ES2219640T3 (es)	2004-12-01
DE69333484D1 (de)	2004-05-19
ATE264388T1 (de)	2004-04-15
DK0589840T3 (da)	2004-07-26
CA2106719C (en)	2006-03-28
KR100298608B1 (ko)	2001-11-22
CN1088986A (zh)	1994-07-06
EP1452542A2 (en)	2004-09-01
FI934145L (fi)	1994-03-25
CN1428352A (zh)	2003-07-09
EP0589840B1 (en)	2004-04-14
AU675449B2 (en)	1997-02-06
DE69333484T2 (de)	2005-03-24
KR940006602A (ko)	1994-04-25
JP3718214B2 (ja)	2005-11-24
NZ248743A (en)	1995-04-27
CY2583B2 (en)	2009-11-04
PT589840E (pt)	2004-08-31
JPH06225788A (ja)	1994-08-16
JP3636737B2 (ja)	2005-04-06
CN1254487C (zh)	2006-05-03
MX9305920A (es)	1994-05-31
EP1452542A3 (en)	2007-05-02
AU4748893A (en)	1994-03-31
CA2106719A1 (en)	1994-03-25
IL107049A (en)	2006-07-05
NO933394L (no)	1994-03-25
NO933394D0 (no)	1993-09-23
FI114550B (fi)	2004-11-15
FI115838B (fi)	2005-07-29
JP2004357712A (ja)	2004-12-24
IL107049A0 (en)	1993-12-28
EP0589840A1 (en)	1994-03-30
IL173988A0 (en)	2006-07-05
FI934145A0 (fi)	1993-09-22
NO318210B1 (no)	2005-02-21
CN1078250C (zh)	2002-01-23
FI20040696L (fi)	2004-05-19

Publication	Publication Date	Title
CY2583B2 (en)	2009-11-04	Reshaped monoclonal antibodies against an immunoglobulin isotype
TR199900722T2 (xx)	1999-12-21	Yeniden kurulmu� insan anti-HM1.24 antikoru.
FR12C0004I1 (zh)	2012-02-24
DK0758904T3 (da)	2010-01-18	Fremgangsmåder og sammensætninger til behandling af glomerulonephritis
HUT74272A (en)	1996-11-28	Immunoglobulin g concentrate for therapeutical use and method for producing same
ATE233814T1 (de)	2003-03-15	Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
ATE166230T1 (de)	1998-06-15	Verwendung von anti-icam antikörpern zur herstellung eines präparats für die behandlung von endotoxinschock
ATE151078T1 (de)	1997-04-15	Verfahren und zwischenprodukte synthetischer antikörperderivate
MX9301858A (es)	1994-03-31	Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
EP0396505A3 (en)	1991-04-03	Monoclonal antibodies specific for an immunoglobulin isotype
ES2100892T3 (es)	1997-07-01	Tratamiento de enfermedades autoinmunitarias.
DK0585570T3 (da)	1999-08-02	Granulocytbindende antistofkonstrukter, deres fremstilling og anvendelse
RU93035807A (ru)	1997-02-27	Способ лечения юношеского эпифизиолиса
GB9220228D0 (en)	1992-11-04	Reshaped monoclonal antibodies against an immunologlobulin isotype

Legal Events

Date	Code	Title	Description
2011-05-06	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20100924